Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03238274 · ClinicalTrials.gov registry record

Sofia 2 Lyme FIA Whole Blood Clinical Study

A clinical trial of Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans), sponsored by Quidel Corporation.

Completed
Registry status
597
Enrollment target
11
Study locations

NCT03238274 is a study of Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans) that has completed, run by Quidel Corporation. The registered enrollment target is 597 participants. The trial reports 11 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03238274, a study of Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans), has completed, sponsored by Quidel Corporation.

COMPLETED
Registry status
597 participants
Enrollment target
11
Study locations

Study Summary

The objective of this study is to demonstrate the clinical performance of the Sofia® 2 analyzer and Sofia Lyme FIA test in the CLIA waived test environment in comparison to Comparator Method(s) and/or an FDA cleared predicate test(s) using matched finger-stick, whole blood and serum from symptomatic subjects.

Interventions

  • DEVICE Sofia 2 Lyme FIA testing

Study Locations (11)

Rhode Island

  • Lincoln Primary Care - Lincoln
  • The Miriam Hospital - Providence
  • Center for Medical Research, LLC - Providence
  • Ocean State Primary Care - Westerly

Massachusetts

  • NECCR Primacare Research, LLC - Fall River
  • Main Road Family Medicine - South Westport

Pennsylvania

  • Altoona Center for Clinical Research - Duncansville
  • Harleysville Medical Associates - Harleysville

Minnesota

  • Essentia Institute of Rural Health - Duluth

New York

  • Regional Clinical Research - Endwell

Wisconsin

  • Marshfield Clinic Research Institute - Marshfield

Trial Details

FieldValue
Enrollment Target 597 participants
Start Date 2017-06-06
Est. Completion 2017-12-15

Sponsor

Quidel Corporation

9 total trials

What the Registry Record Tells You About NCT03238274

The ClinicalTrials.gov registry entry for NCT03238274 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 597 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quidel Corporation, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans) appearing as the primary indexed condition, and to 1 intervention - of which Sofia 2 Lyme FIA testing is the first listed.

NCT03238274 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Rhode Island, Massachusetts, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03238274 about?

NCT03238274 is a clinical study titled "Sofia 2 Lyme FIA Whole Blood Clinical Study". The objective of this study is to demonstrate the clinical performance of the Sofia® 2 analyzer and Sofia Lyme FIA test in the CLIA waived test environment in comparison to Comparator Method(s) and/or an FDA cleared predicate test(s) using matched finger-stick, whole blood and serum from symptomatic...

What is the current status of trial NCT03238274?

This trial is currently completed. The enrollment target is 597 participants. The study started on 2017-06-06. Estimated completion is 2017-12-15.

What conditions does trial NCT03238274 study?

This clinical trial studies the following conditions: Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans).

What interventions are being tested in trial NCT03238274?

The interventions under investigation include: Sofia 2 Lyme FIA testing (DEVICE).

Who is sponsoring clinical trial NCT03238274?

This trial is sponsored by Quidel Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03238274 being conducted?

This trial has 11 study locations across Massachusetts, Minnesota, New York, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.